Jain N, Keating M, Thompson P, et al. - Previously untreated chronic lymphocytic leukemia (CLL) patients might benefit from combination therapy of ibrutinib and venetoclax. A follow-up of more than 3 years revealed durable remissions, with activity evident across high-risk disease subgroups, including those with del(17p)/TP53-mutated CLL.

• This phase 2 nonrandomized trial involved 80 previously untreated CLL patients.

• Patients were administered combined ibrutinib and venetoclax for 24 cycles.

• On intent-to-treat analysis, 56% of the patients achieved bone marrow–undetectable measurable residual disease remission at 12 cycles and 66% of the patients at 24 cycles of combined therapy.

• As best response, bone marrow–undetectable measurable residual disease remission was achieved by 75% of the patients.

• 3-year progression-free survival and 3-year overall survival was 93% and 96%, respectively.